Literature DB >> 8943305

The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells.

C Brunner1, E M Lobentanz, A Pethö-Schramm, A Ernst, C Kang, H Dieplinger, H J Müller, G Utermann.   

Abstract

A variable number of 5.6-kilobase kringle IV repeats in the human apolipoprotein(a) (apo(a)) gene results in a size polymorphism of the protein and correlates inversely with the plasma levels of the atherogenic lipoprotein(a) (Lp(a)). In order to analyze whether this association reflects a direct effect of kringle IV repeat number on Lp(a) plasma concentration, we have studied the expression of recombinant apo(a) (r-apo(a)) isoforms in the human hepatocarcinoma cell line HepG2. Following transient transfection of apo(a) cDNA expression plasmids that differed only in the number of kringle IV repeats, we observed a gradual decrease of Lp(a) in the medium of the cells with an increasing number of kringle IV repeats, mimicking the relationship present in humans in vivo. The analysis of apo(a) protein in the lysate and in the medium of cells that were transfected with a plasmid encoding an apo(a) isoform with 22 kringles revealed a predominant intracellular precursor with little secretion of the mature apo(a) protein. In contrast, transfection of a plasmid encoding an isoform with 11 kringles led to effective secretion of the mature peptide into the medium, indicating differential processing rates of apo(a) isoforms in the secretory path way. The intracellular accumulation of an apo(a) precursor in the endoplasmic reticulum was demonstrated by cell fractionation and [35S]Met metabolic labeling/temperature block experiments using HepG2 cells stably transfected with recombinant apo(a). The direct and causal effect of kringle IV repeat number on the expression of recombinant apo(a) in HepG2 cells, and presumably liver cells, provides a novel mechanism for the genetic regulation of the concentration of a protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943305     DOI: 10.1074/jbc.271.50.32403

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

2.  Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q.

Authors:  Carole Ober; Alex S Nord; Emma E Thompson; Lin Pan; Zheng Tan; Darren Cusanovich; Ying Sun; Raluca Nicolae; Celina Edelstein; Daniel H Schneider; Christine Billstrand; Ditta Pfaffinger; Natasha Phillips; Rebecca L Anderson; Binu Philips; Ramakrishnan Rajagopalan; Thomas S Hatsukami; Mark J Rieder; Patrick J Heagerty; Deborah A Nickerson; Mark Abney; Santica Marcovina; Gail P Jarvik; Angelo M Scanu; Dan L Nicolae
Journal:  J Lipid Res       Date:  2009-01-05       Impact factor: 5.922

Review 3.  Screening for and management of elevated Lp(a).

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

Review 4.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

5.  Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk.

Authors:  James Ronald; Ramakrishnan Rajagopalan; Felecia Cerrato; Alex S Nord; Thomas Hatsukami; Ted Kohler; Santica Marcovina; Patrick Heagerty; Gail P Jarvik
Journal:  Stroke       Date:  2010-12-02       Impact factor: 7.914

6.  Nonsynonymous SNPs in LPA homologous to plasminogen deficiency mutants represent novel null apo(a) alleles.

Authors:  Benjamin M Morgan; Aimee N Brown; Nikita Deo; Tom W R Harrop; George Taiaroa; Peter D Mace; Sigurd M Wilbanks; Tony R Merriman; Michael J A Williams; Sally P A McCormick
Journal:  J Lipid Res       Date:  2019-12-05       Impact factor: 5.922

7.  Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans.

Authors:  J-P Chretien; J Coresh; Y Berthier-Schaad; W H L Kao; N E Fink; M J Klag; S M Marcovina; F Giaculli; M W Smith
Journal:  J Med Genet       Date:  2006-07-13       Impact factor: 6.318

Review 8.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

9.  Lipoprotein(a) and cardiovascular disease in diabetic patients.

Authors:  Qibin Qi; Lu Qi
Journal:  Clin Lipidol       Date:  2012-08

10.  Do We Know When and How to Lower Lipoprotein(a)?

Authors:  Parag H Joshi; Eric Krivitsky; Zhen Qian; Gustavo Vazquez; Szilard Voros; Joseph Miller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.